Archive for the 'Peritoneal (Abdominal Mesothelioma)' Category
Malignant peritoneal mesothelioma; cancer of the lining of the abdominal caviety.
November 17th, 2007. What is the role of diagnostic laparoscopy in a gastroenterology unit?
Conclusions: Diagnostic laparoscopy in a gastroenterology unit is safe and useful, especially for confirmation of liver cirrhosis and primary peritoneal disease evaluation.
November 3rd, 2007. Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals
Higher survival rates can be reached in ovarian cancer, which is commonly diagnosed in the presence of peritoneal carcinomatosis, using an optimal cytoreductive radical surgery with intraperitoneal chemotherapy. An actualised review of the treatment of advanced ovarian cancer and a proposal of a national multicentre protocol for the treatment of peritoneal carcinomatosis from ovarian cancer has been performed by a group of Spanish surgeons and oncologists dedicated to a therapeutical approach to this pathology.
November 1st, 2007. Peritoneal mesothelioma presenting as an acute surgical abdomen due to jejunal perforation
Conclusions: Peritoneal mesothelioma is a rare malignancy with grim prognosis. Small bowel involvement is a poor prognostic indicator. Our case of a small bowel perforation due to direct infiltration by peritoneal mesothelioma appears to be the first reported in the English literature.
Posted in Case Study, Chemotherapy, Diagnosis & Differentiation, Full Archive, Immunohistochemistry or IHC, Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
October 24th, 2007. Immunohistochemical Detection of XIAP in Mesothelium and Mesothelial Lesions
XIAP immunostaining, when strong, allows for distinction of malignant from benign and hyperplastic mesothelial cell populations and is a potentially useful immunodiagnostic marker in small samples and morphologically controversial cases. Elevated expression of XIAP could contribute to tumorigenesis in mesothelioma.
October 24th, 2007. Peritoneal mesothelioma: a review
The incidence has increased in the past 2 decades. Only 20% to 33% of all mesotheliomas arise from the peritoneum itself; the pleura is the most common site of origin.
October 9th, 2007. Alpha-Tocopheryl succinate: Toxicity and lack of anti-tumour activity in immuno-competent mice
Toxicity of α-TOS has not been reported to date perhaps due to a lack of studies conducted in fully immuno-competent hosts. Our results suggest that the translation of animal studies to clinical treatment with α-TOS requires careful consideration.
September 22nd, 2007. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?
Taken together, we suggest that PAX2 is a novel Müllerian-specific epithelial marker when used in proper clinical settings. Identification of PAX2 in the majority of papillary serous carcinomas of the ovary but not in the ovarian surface epithelium or epithelium-derived inclusion cysts suggests that this malignant epithelial tumor may be directly derived from the primary or secondary Müllerian epithelium in or surrounding the ovary, rather than from the surface epithelium or its derivatives.
August 24th, 2007. Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel
Conclusion: The combination of radiotherapy and intraperitoneal paclitaxel seems suitable in palliative settings primarily aimed at improving the quality of life.
August 22nd, 2007. Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings
We present a summary of cytologic features that, in our experience, we find to be most useful in making or excluding a diagnosis of PPM. To our knowledge, this is the first large series reporting the cytomorphologic features of PPM in peritoneal effusions, pelvic washing specimens, and infradiaphragmatic fine-needle aspiration biopsy specimens.
August 2nd, 2007. h-Caldesmon, Calretinin, Estrogen Receptor, and Ber-EP4: A Useful Combination of Immunohistochemical Markers for Differentiating Epithelioid Peritoneal Mesothelioma From Serous Papillary Carcinoma of the Ovary
3%). The relationship between the values of sensitivity and specificity of each marker using receiver operating characteristic analysis permitted the identification of h-CD, calretinin, ER, and Ber-EP4 as the markers with the best performance in differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
July 31st, 2007. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC)
Conclusions: MPM and WDPPM are borderline tumors capable of transformation into potentially lethal processes. Definitive tumor eradication by means of cytoreduction and HIPEC seems more effective than debulking surgery in preventing disease recurrence or transition to aggressive malignancies.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Diffuse mesothelioma, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 26th, 2007. Dextran-based in situ cross-linked injectable hydrogels to prevent peritoneal adhesions
However, all cross-linked gels had very mild cytotoxicity. When applied in a rabbit sidewall defect-bowel abrasion model of adhesion formation, CMDX–CMC greatly reduced the formation of adhesions while CMDX–DX worsened them.
July 25th, 2007. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
Conclusions: LMW forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and were associated with increased protein expression using immunohistochemistry. The expression of LMW cyclin E forms was not associated with chemotherapy response, although it may be a marker of aggressive disease in patients with metastatic ovarian carcinoma.
July 18th, 2007. Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma
Finally, although the intensity of therapy is considerable, once recovered, the patients appear to enjoy a good HRQOL. Although not specific for patients with MPM, 2 reports have convincingly demonstrated that HRQOL is significantly improved after HIPEC.
Posted in Chemotherapy, CT or CAT scan, Determining Efficacy, Diagnosis & Differentiation, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 14th, 2007. The use of peritoneal mesothelium as a potential source of adult stem cells
The main concept emerging from this information is that peritoneal mesothelial cells are endowed with such a degree of plasticity that, if placed in the appropriate micro-environment, they have a remarkable potential to generate other mesenchymal-derived cell lines. Intensive research is required to define the best environmental conditions to take advantage of this plasticity and make the peritoneal mesothelium an actual option to be applied in regenerative medicine.
June 15th, 2007. Generation and characterization of an ascitogenic mesothelin-expressing tumor model
Conclusion: The data indicate that the WF-3 murine tumor model may potentially serve as a good model for understanding the molecular oncogenesis of peritoneal tumors. In addition, the preclinical model may potentially be useful for the development of diagnostic and therapeutic methods against intraperitoneal cancers.
June 15th, 2007. Asbestos exposure and differences in occurrence of peritoneal mesothelioma in the Netherlands and Sweden
Conclusion: The absence of a time trend in the incidence rate of peritoneal mesothelioma in the Netherlands and Sweden in the past 15 years may point at a more limited role of occupational exposure to asbestos in the etiology of peritoneal mesothelioma than for pleural mesothelioma, especially among women. The observed drop around 2000 in annual incidence of peritoneal mesothelioma among Swedish women indicates the presence in the past of a substantial misclassification with other tumours in the peritoneum.
Posted in Causation, Diagnosis & Differentiation, Environmental Asbestos Exposure, Epidemiological, Full Archive, General, Occupational Asbestos Exposure, Peritoneal (Abdominal Mesothelioma), Pleural, Type of Assessment:, Type of Mesothelioma: | No Comments »
June 5th, 2007. Benign peritoneal cystic mesothelioma as differential diagnose of an ovarian dependant tumor. Case report and review of the literature
Despite the low incidence of this tumoration the gynecologist must be familiar with this disease, because of the high recurrence. Nowadays, steroid hormone receptors typification seems to play an important role to control the recurrence of this tumoration.
May 11th, 2007. So13p cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma – analysis of 100 consecutive patients from a prospective database
Conclusions: CRS and PIC showed an improved survival for DMPM, as compared to historical controls. Long-term survival was associated with female gender, absence of lymph node involvement, epithelial or multicystic type and adequate cytoreduction.
Posted in Chemotherapy, Determining Efficacy, Diffuse mesothelioma, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
May 11th, 2007. So12p combined cytoreductive surgery and perioperative intraperitoneal chemotherapy in the treatment of peritoneal mesothelioma
Conclusion: CRS combined with PIC is a treatment option for peritoneal mesothelioma that confers improved survival, when compared with historical controls using systemic chemotherapy.
Posted in Causation, Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Occupational Asbestos Exposure, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
|
|  |
